Pediatrix Medical Group, Inc. (MD) SEC Filings & Earnings Calls
EquiReason read 12 Pediatrix Medical Group, Inc. SEC filings in the last 12 months. Latest: 10-Q on 2026-08-04 — Pediatrix reported Q2 2026 revenue of $487.8M (+4% YoY), net income of $39.8M (+1.5% YoY), and Adjusted EPS of $0.63 (+18.9% YoY), with operating margin declining 110bps to 11.7%..
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 2.4B
- P/E TTM
- 14.0
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
4 Aug 202610-QPediatrix reported Q2 2026 revenue of $487.8M (+4% YoY), net income of $39.8M (+1.5% YoY), and Adjusted EPS of $0.63 (+18.9% YoY), with operating margin declining 110bps to 11.7%.earningsopen
Figures in the filing · each found in the filing text
| Net revenue · Q2-2026 | $488M | +4% y/y |
| Net income · Q2-2026 | $40M | +2% y/y |
| Adjusted EBITDA · Q2-2026 | $76M | +4% y/y |
| Adjusted EPS · Q2-2026 | $0.63 | +19% y/y |
| Operating cash flow · H1-2026 | $-3M | |
| Days Sales Outstanding · Q2-2026 | 42.5 | -8% y/y |
| Stock repurchases · H1-2026 | $64M |
Risks flagged
Medicaid reform reduces reimbursement
“The Congressional Budget Office has estimated that the One Big Beautiful Bill Act will cut federal spending on Medicaid and Children’s Health Insurance Program benefits by $900 billion, due in part to eliminating millions of people from the programs by 2034.” · word for word
Medicare fee schedule cut
“In July 2026, CMS released the 2027 Medicare Physician Fee Schedule, which proposes to reduce the conversion factor by 1.19% for 2027.” · word for word
Surprise billing legislation uncertainty
“In May 2026, CMS finalized the most comprehensive revisions to the IDR process since its implementation. These measures could limit the amount we can charge and recover for services we furnish where we have not contracted with the patient’s insurer.” · word for word
Operating cash flow negative
“During the six months ended June 30, 2026, our net cash used in operating activities from continuing operations was $3.2 million, compared to cash provided of $22.0 million for the same period in 2025.” · word for word
4 Aug 20268-K · 2.02Net Revenue $488M (+4% y/y); Net Income $40M (+1% y/y); Adjusted EBITDA $76M (+4% y/y)earningsopen
Figures in the filing · each found in the filing text
| Net Revenue · Q2-2026 | $488M | +4% y/y |
| Net Income · Q2-2026 | $40M | +1% y/y |
| Adjusted EBITDA · Q2-2026 | $76M | +4% y/y |
| Adjusted EPS · Q2-2026 | $0.63 | +19% y/y |
| Cash and Cash Equivalents · Q2-2026 | $289M | |
| Diluted EPS · Q2-2026 | $0.49 | +7% y/y |
| Same-Unit Revenue Growth · Q2-2026 | 1.9% |
Risks flagged
Patient volume declining 2.1% same-unit, indicating potential demand weakness.
“Same-unit patient volume decreased 2.1%.”
Transformational and restructuring expenses increased to $8.5M from $3.8M.
“Transformational and restructuring related expenses $8.5M.”
24 Jul 20268-K · 5.02, 7.01Departure of EVP/General Counsel/CAO and appointment of new EVP/General Counsel/Secretary; separation agreement with advisory role through Oct 31, 2026.open
Risks flagged
Loss of experienced executive; transition risk in legal and administrative functions.
“Departure of EVP, General Counsel, Chief Administrative Officer and Secretary.”
15 Jul 20268-K · 2.02, 7.01Adjusted EBITDA guidance $280M; Guidance: Adjusted EBITDA $280M-$300Mearningsopen
Figures in the filing · each found in the filing text
| Adjusted EBITDA guidance · FY2026 | $280M |
Guidance
Adjusted EBITDA $280M-$300M
Guidance reaffirmed with stable payor mix and revenue trends.
Risks flagged
Potential payor mix shifts and reimbursement pressures in healthcare sector could impact future results.
“Company confirms payor mix stable to date, but industry reports indicate shifting utilization and reimbursement trends.”
7 May 20268-K · 5.02, 5.07Reported the departure of a director or principal officer (CEO/CFO change); submitted matters to a vote of security holdersopen
Risks flagged
Potential shareholder dilution from increased equity plan shares.
“increased the number of shares of the Company’s common stock available for issuance under the Plan by 8,000,000 shares.”
5 May 202610-QNet revenue $476M (+4% y/y); Net income $30M (+43% y/y); Adjusted EBITDA $58M (+18% y/y)open
Figures in the filing · each found in the filing text
| Net revenue · Q1-2026 | $476M | +4% y/y |
| Net income · Q1-2026 | $30M | +43% y/y |
| Adjusted EBITDA · Q1-2026 | $58M | +18% y/y |
| Adjusted EPS · Q1-2026 | $0.44 | +33% y/y |
| Diluted EPS · Q1-2026 | $0.36 | +50% y/y |
| Operating margin · Q1-2026 | 8.7% | |
| Days sales outstanding · Q1-2026 | $42.50 | -11% y/y |
| Operating cash flow · Q1-2026 | $-130M | +12% y/y |
| Share repurchases · Q1-2026 | $22M |
Risks flagged
Medicaid reimbursement cuts
“The Congressional Budget Office has estimated that the One Big Beautiful Bill Act will cut federal spending on Medicaid and Children’s Health Insurance Program benefits by $1 trillion, due in part to eliminating at least 10.5 million people from the programs by 2034.” · word for word
Surprise billing legislation impact
“These measures could limit the amount we can charge and recover for services we furnish where we have not contracted with the patient’s insurer, and therefore could have a material adverse effect on our business.” · word for word
Debt maturity concentration
“The Amended Credit Agreement matures on February 11, 2027 and is guaranteed on an unsecured basis by substantially all of our subsidiaries and affiliated professional contractors.” · word for word
5 May 20268-K · 2.02Net revenue $476M (+4% y/y); Net income $30M (+43% y/y); Adjusted EBITDA $58M (+18% y/y)earningsopen
Figures in the filing · each found in the filing text
| Net revenue · Q1-2026 | $476M | +4% y/y |
| Net income · Q1-2026 | $30M | +43% y/y |
| Adjusted EBITDA · Q1-2026 | $58M | +18% y/y |
| Adjusted EPS · Q1-2026 | $0.44 | +33% y/y |
| Diluted earnings per share · Q1-2026 | $0.36 | +50% y/y |
| Cash and cash equivalents · Q1-2026 | $206M | |
| Net accounts receivable · Q1-2026 | $225M |
Risks flagged
Patient volume declining (hospital-based -1.5%, office-based -3.3%) may pressure future revenue if not offset by reimbursement gains.
“Hospital-based patient services (1.5)%; Office-based patient services (3.3)%” · word for word
Seasonal cash flow use; cash balance declined significantly from year-end.
“Cash and cash equivalents of $205.8 million at March 31, 2026, compared to $375.2 million at December 31, 2025” · word for word
27 Mar 2026DEF 14AProxy statement disclosing executive compensation structure, pay-for-performance alignment, and shareholder advisory votes.open
Figures in the filing · each found in the filing text
| Adjusted Income from Operations · FY2025 | $231M | +26% y/y |
| Adjusted EBITDA · FY2025 | $276M | +23% y/y |
| Net Income (Loss) · FY2025 | $165M | |
| Total Shareholder Return (1-year) · FY2025 | $87.16 | +63% y/y |
| Peer Group Total Shareholder Return · FY2025 | $77.88 | -1% y/y |
Risks flagged
Reimbursement Pressure
“We continue to operate in a dynamic healthcare environment characterized by reimbursement pressures and labor market challenges” · word for word
Labor Market Challenges
“We continue to operate in a dynamic healthcare environment characterized by reimbursement pressures and labor market challenges” · word for word
Payor Mix Shift Risk
“Payor mix shifts, which represents a shift in the patient population from private healthcare insurance programs (i.e., commercial programs) to government-sponsored healthcare programs (i.e., Medicaid), are extremely difficult to forecast over both short- and long-term periods.” · word for word
19 Feb 202610-KTotal indebtedness $597M; Days sales outstanding 42.8; Share repurchase authorization remaining $166Mopen
Figures in the filing · each found in the filing text
| Total indebtedness · FY2025 | $597M | |
| Days sales outstanding · FY2025 | $42.80 | |
| Share repurchase authorization remaining · FY2025 | $166M |
Risks flagged
Medicaid reimbursement cut risk
“The Congressional Budget Office has estimated that the One Big Beautiful Bill Act will cut federal spending on Medicaid and Children’s Health Insurance Program benefits by $1 trillion, due in part to eliminating at least 10.5 million people from the programs by 2034.” · word for word
Physician shortage and labor cost risk
“The U.S. is currently experiencing and is expected to continue to experience a nationwide healthcare professional shortage.” · word for word
Interest rate risk on variable debt
“If interest rates continue to increase, any variable rate debt will create higher debt service requirements” · word for word
Geographic concentration risk
“During 2025 and 2024, approximately 64% and 67%, respectively, of our net revenue was generated by operations in our five largest states.” · word for word
19 Feb 20268-K · 2.02Net revenue $494M (-2% y/y); Adjusted EBITDA $66M (-4% y/y); Adjusted EPS $0.50 (-2% y/y); Guidance: Revised upward expectationsearningsopen
Figures in the filing · each found in the filing text
| Net revenue · Q4-2025 | $494M | -2% y/y |
| Adjusted EBITDA · Q4-2025 | $66M | -4% y/y |
| Adjusted EPS · Q4-2025 | $0.50 | -2% y/y |
| Same-unit net revenue growth · Q4-2025 | 4.0% |
Guidance
Revised upward expectations
CEO stated Q4 results were in line with revised upward expectations; guidance raised.
Risks flagged
Volume decline in hospital-based and office-based services
“Hospital-based patient services volume decreased 3.3% year-over-year; office-based decreased 2.3%”
3 Nov 202510-QQ3 2025 earnings: net income $71.7M vs $19.4M YoY, operating margin 13.8% vs 6.6%, Adjusted EBITDA $87.3M vs $60.2Mearningsopen
Figures in the filing · each found in the filing text
| Revenue · Q3-2025 | $493M | -4% y/y |
| Net income · Q3-2025 | $72M | +269% y/y |
| Adjusted EBITDA · Q3-2025 | $87M | +45% y/y |
| Adjusted EPS · Q3-2025 | $0.67 | +52% y/y |
| Operating cash flow · 9M-2025 | $160M | +94% y/y |
| Days Sales Outstanding · 2025-09-30 | $43.10 | -17% y/y |
| Cash and cash equivalents · 2025-09-30 | $340M | |
| Stock repurchases · 9M-2025 | $23M |
Risks flagged
Exposure to government reimbursement changes
“Payments received from GHC Programs are substantially less for equivalent services than payments received from commercial insurance payors.” · word for word
Surprise billing legislation impact
“These measures could limit the amount we can charge and recover for services we furnish where we have not contracted with the patient's insurer, and therefore could have a material adverse effect on our business.” · word for word
3 Nov 20258-K · 2.02Net revenue $493M; Net income $72M; Adjusted EBITDA $87M; Guidance: Full year 2025 Adjusted EBITDA likely range between $270 million and $290 millionearningsopen
Figures in the filing · each found in the filing text
| Net revenue · Q3-2025 | $493M | |
| Net income · Q3-2025 | $72M | |
| Adjusted EBITDA · Q3-2025 | $87M | |
| Adjusted EPS · Q3-2025 | $0.67 | |
| Same-unit net revenue growth · Q3-2025 | 8.0% | |
| Same-unit revenue from net reimbursement-related factors · Q3-2025 | 7.6% | |
| Same-unit revenue attributable to patient service volumes · Q3-2025 | 0.4% | |
| NICU days growth · neonatology · Q3-2025 | 2.2% | |
| Practice salaries and benefits expense · Q3-2025 | $332M | |
| General and administrative expenses · Q3-2025 | $61M |
Guidance
Full year 2025 Adjusted EBITDA likely range between $270 million and $290 million
Raised full year 2025 Adjusted EBITDA outlook range to $270M-$290M; Q3 results exceeded expectations.
Risks flagged
Healthcare environment uncertainty; potential regulatory changes.
“know that they come at a time of change and uncertainty in the healthcare environment.” · word for word
Pediatrix Medical Group, Inc. — questions
- What did Pediatrix Medical Group, Inc. file recently?
- 12 SEC filings in the last 12 months. Latest: 10-Q on 2026-08-04 — Pediatrix reported Q2 2026 revenue of $487.8M (+4% YoY), net income of $39.8M (+1.5% YoY), and Adjusted EPS of $0.63 (+18.9% YoY), with operating margin declining 110bps to 11.7%.
Every figure on this page comes from Pediatrix Medical Group, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.